Related references
Note: Only part of the references are listed.Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies
Min Hwan Kim et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2017)
Markers of Hippo-Pathway Activity in Tumor Forming Liver Lesions
Henning Reis et al.
PATHOLOGY & ONCOLOGY RESEARCH (2017)
Hippo Signaling in the Liver Regulates Organ Size, Cell Fate, and Carcinogenesis
Sachin H. Patel et al.
GASTROENTEROLOGY (2017)
Modulating the wnt signaling pathway with small molecules
Freddi Huan Tran et al.
PROTEIN SCIENCE (2017)
Targeting Tankyrase to Fight WNT-dependent Tumours
Tor Espen Thorvaldsen
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY (2017)
Inactivation of Hippo Pathway Is Significantly Associated with Poor Prognosis in Hepatocellular Carcinoma
Bo Hwa Sohn et al.
CLINICAL CANCER RESEARCH (2016)
Non-Photoinduced Biological Properties of Verteporfin
Floriane Gibault et al.
CURRENT MEDICINAL CHEMISTRY (2016)
YAP/TAZ as therapeutic targets in cancer
Francesca Zanconato et al.
CURRENT OPINION IN PHARMACOLOGY (2016)
Tankyrase Inhibitor Sensitizes Lung Cancer Cells to Endothelial Growth Factor Receptor (EGFR) Inhibition via Stabilizing Angiomotins and Inhibiting YAP Signaling
Hui Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
RNAi-nanoparticulate manipulation of gene expression as a new functional genomics tool in the liver
Hao Yin et al.
JOURNAL OF HEPATOLOGY (2016)
Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells
Xiao-Yang Dai et al.
ONCOTARGET (2016)
Angiomotin stabilization by tankyrase inhibitors antagonizes constitutive TEAD-dependent transcription and proliferation of human tumor cells with Hippo pathway core component mutations
Albino Troilo et al.
ONCOTARGET (2016)
Hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer
Fa-Xing Yu et al.
CELL (2015)
Chemical Disruption of Wnt-dependent Cell Fate Decision-making Mechanisms in Cancer and Regenerative Medicine
L. Lum et al.
CURRENT MEDICINAL CHEMISTRY (2015)
Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer
Dean Yimlamai et al.
JOURNAL OF HEPATOLOGY (2015)
Knockdown of yes-associated protein inhibits proliferation and downregulates large tumor suppressor 1 expression in MHCC97H human hepatocellular carcinoma cells
Cheng Wang et al.
MOLECULAR MEDICINE REPORTS (2015)
Co-activation of PIK3CA and Yap promotes development of hepatocellular and cholangiocellular tumors in mouse and human liver
Xiaolei Li et al.
ONCOTARGET (2015)
Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells
Li Ma et al.
ONCOTARGET (2015)
Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins
Wenqi Wang et al.
CELL REPORTS (2015)
Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma
Florian Ewald et al.
JOURNAL OF CANCER (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Tankyrases: Structure, Function and Therapeutic Implications in Cancer
Teemu Haikarainen et al.
CURRENT PHARMACEUTICAL DESIGN (2014)
The Angiomotins - From discovery to function
Susana Moleirinho et al.
FEBS LETTERS (2014)
Activation of β-Catenin and Yap1 in Human Hepatoblastoma and Induction of Hepatocarcinogenesis in Mice
Junyan Tao et al.
GASTROENTEROLOGY (2014)
YAP activation is an early event and a potential therapeutic target in liver cancer development
Andrea Perra et al.
JOURNAL OF HEPATOLOGY (2014)
MK2206 inhibits hepatocellular carcinoma cellular proliferation via induction of apoptosis and cell cycle arrest
J. M. Wilson et al.
JOURNAL OF SURGICAL RESEARCH (2014)
Recent advances in the structure-based rational design of TNKSIs
Peng Zhan et al.
MOLECULAR BIOSYSTEMS (2014)
Regulation of Hippo Signaling by EGFR-MAPK Signaling through Ajuba Family Proteins
B. V. V. G. Reddy et al.
DEVELOPMENTAL CELL (2013)
Tankyrases as drug targets
Lari Lehtio et al.
FEBS JOURNAL (2013)
Yes-Associated Protein Up-regulates Jagged-1 and Activates the NOTCH Pathway in Human Hepatocellular Carcinoma
Darjus Felix Tschaharganeh et al.
GASTROENTEROLOGY (2013)
Structural Basis and SAR for G007-LK, a Lead Stage 1,2,4-Triazole Based Specific Tankyrase 1/2 Inhibitor
Andrew Voronkov et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma
Xinying Huo et al.
ONCOLOGY REPORTS (2013)
Role of TAZ as Mediator of Wnt Signaling
Luca Azzolin et al.
CELL (2012)
Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP
Yi Liu-Chittenden et al.
GENES & DEVELOPMENT (2012)
Increased Lipogenesis, Induced by AKT-mTORC1-RPS6 Signaling, Promotes Development of Human Hepatocellular Carcinoma
Diego F. Calvisi et al.
GASTROENTEROLOGY (2011)
E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer
Sara Ladu et al.
GASTROENTEROLOGY (2008)
Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
Augusto Villanueva et al.
GASTROENTEROLOGY (2008)
TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal
Xaralabos Varelas et al.
NATURE CELL BIOLOGY (2008)
Ubiquitous activation of Ras and Jak/Stat pathways in human HCC
DF Calvisi et al.
GASTROENTEROLOGY (2006)
The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer
Patrick J. Klein et al.
NEOPLASIA (2006)
Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis
P Laurent-Puig et al.
GASTROENTEROLOGY (2001)
Share Paper
